← All trials
NCT01345240
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Jan 1, 2013
- Completion date
- Feb 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 705
- Arms / groups
- 11 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- gsk 257049
- hepatitis b vaccine (recombinant)
- hepatitis b vaccine (recombinant)
- attenuated measles vaccine - Edmonston strain
- attenuated measles vaccine - Edmonston strain
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- live oral poliovirus type 1, 2 and 3
- live oral poliovirus type 1, 2 and 3
- 10-valent Pneumococcal Conjugate Vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- human rotavirus, live attenuated
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.